X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
aged (12) 12
female (12) 12
index medicus (12) 12
male (11) 11
middle aged (11) 11
chemotherapy (9) 9
lung cancer, non-small cell (9) 9
cancer (8) 8
carcinoma, non-small-cell lung - drug therapy (8) 8
lung neoplasms - drug therapy (8) 8
clinical trials (7) 7
lung neoplasms - pathology (7) 7
oncology (7) 7
aged, 80 and over (6) 6
care and treatment (6) 6
disease-free survival (6) 6
lung cancer (6) 6
carcinoma, non-small-cell lung - pathology (5) 5
lung neoplasms - mortality (5) 5
product development (5) 5
treatment outcome (5) 5
abridged index medicus (4) 4
adult (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
carcinoma, non-small-cell lung - mortality (4) 4
gefitinib (4) 4
hematology, oncology and palliative medicine (4) 4
lung neoplasms - genetics (4) 4
patients (4) 4
receptor, epidermal growth factor - genetics (4) 4
tumors (4) 4
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
carboplatin (3) 3
carboplatin - administration & dosage (3) 3
carcinoma, non-small-cell lung - therapy (3) 3
cisplatin - administration & dosage (3) 3
epidermal growth factor receptors (3) 3
erlotinib (3) 3
medicine, general & internal (3) 3
neutropenia (3) 3
non-small-cell lung cancer (3) 3
prospective studies (3) 3
quinazolines - therapeutic use (3) 3
therapy (3) 3
1st-line treatment (2) 2
analysis (2) 2
article (2) 2
bevacizumab - administration & dosage (2) 2
cisplatin (2) 2
combination (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
dosage and administration (2) 2
egfr (2) 2
elderly (2) 2
erlotinib hydrochloride - therapeutic use (2) 2
gemcitabine (2) 2
hospitals (2) 2
internal medicine (2) 2
kaplan-meier estimate (2) 2
life sciences (2) 2
lung cancer, small cell (2) 2
lung neoplasms - therapy (2) 2
medicine & public health (2) 2
metastases (2) 2
metastasis (2) 2
multicenter (2) 2
mutation (2) 2
mutations (2) 2
neoplasm staging (2) 2
neoplasms (2) 2
non-small cell lung cancer (2) 2
ovarian cancer (2) 2
pemetrexed - administration & dosage (2) 2
predictive value of tests (2) 2
proportional hazards models (2) 2
proteins (2) 2
quinazolines - adverse effects (2) 2
radiology, nuclear medicine & medical imaging (2) 2
research (2) 2
respiratory system (2) 2
studies (2) 2
surgery (2) 2
survival (2) 2
survival analysis (2) 2
toxicity (2) 2
trial (2) 2
tyrosine (2) 2
1st-line therapy (1) 1
205923-56-4 (1) 1
918504-65-1 (1) 1
[chim]chemical sciences (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
adenocarcinoma (1) 1
adjuvants (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9652, pp. 1809 - 1818
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 74, Issue 6, pp. 1077 - 1085
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 7/2013, Volume 40, Issue 7, pp. 985 - 996
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2009, Volume 73, Issue 4, pp. 1069 - 1076
Purpose To determine the efficacy of motexafin gadolinium (MGd) in combination with whole brain radiotherapy (WBRT) for the treatment of brain metastases from... 
Radiology | Hematology, Oncology and Palliative Medicine | Non–small-cell lung cancer | Brain metastases | Whole brain radiotherapy | Neurocognitive function | Motexafin gadolinium | Neurologic progression | Non-small-cell lung cancer | SURVIVAL | RANDOMIZED-TRIAL | RADIATION | METABOLISM | ONCOLOGY | TEXAPHYRIN | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Carcinoma, Non-Small-Cell Lung - radiotherapy | Humans | Middle Aged | Proportional Hazards Models | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Lung Neoplasms | Cranial Irradiation - methods | Cognition Disorders - diagnosis | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - therapy | Metalloporphyrins - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Agents - adverse effects | Cognition Disorders - etiology | Brain Neoplasms - therapy | Female | Aged | Combined Modality Therapy - methods | Carcinoma, Non-Small-Cell Lung - drug therapy | Brain Neoplasms - radiotherapy | Metalloporphyrins - adverse effects | Care and treatment | Clinical trials | Gadolinium | Product development | Metastasis | Lung cancer, Non-small cell | Radiotherapy | Index Medicus | SURGERY | GADOLINIUM | PATIENTS | LUNGS | METASTASES | RADIATION DOSES | TOXICITY | LIVER | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | HYPERTENSION | BRAIN
Journal Article